StockData
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc. (FHTX) stock

FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/30
$1.79−0.04 (-2.19%)

Close on Nov 18, 2026Market cap $106.30MP/E –Yield –

Foghorn Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Foghorn Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$84.29M. For fiscal 2025 it was -$86.15M. The highest annual figure on record is $192.40M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$86.15M–
FY2024Dec 31, 2024-$101.31M–
FY2023Dec 31, 2023-$119.33M-162.0%
FY2022Dec 31, 2022$192.40M–
FY2021Dec 31, 2021-$53.56M–
FY2020Dec 31, 2020-$47.47M–
FY2019Dec 31, 2019-$47.30M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.89M–
Q1 FY2026Mar 31, 2026-$25.27M–
Q4 FY2025Dec 31, 2025-$22.27M–
Q3 FY2025Sep 30, 2025-$18.86M–
Q2 FY2025Jun 30, 2025-$21.02M–
Q1 FY2025Mar 31, 2025-$24.00M–
Q4 FY2024Dec 31, 2024-$25.00M–
Q3 FY2024Sep 30, 2024-$21.31M–
Q2 FY2024Jun 30, 2024-$25.55M–
Q1 FY2024Mar 31, 2024-$29.45M–
Q4 FY2023Dec 31, 2023-$27.58M–
Q3 FY2023Sep 30, 2023-$27.29M–
Q2 FY2023Jun 30, 2023-$32.64M–
Q1 FY2023Mar 31, 2023-$31.82M-111.7%
Q4 FY2022Dec 31, 2022-$29.19M-347.4%
Q3 FY2022Sep 30, 2022-$20.32M–
Q2 FY2022Jun 30, 2022-$29.38M–
Q1 FY2022Mar 31, 2022$271.29M–
Q4 FY2021Dec 31, 2021$11.80M–
Q3 FY2021Sep 30, 2021-$20.73M–
Q2 FY2021Jun 30, 2021-$19.69M–
Q1 FY2021Mar 31, 2021-$24.94M–
Q4 FY2020Dec 31, 2020-$18.14M–
Q3 FY2020Sep 30, 2020-$2.70M–
Q2 FY2020Jun 30, 2020-$14.84M–
Q1 FY2020Mar 31, 2020-$11.78M–
Q4 FY2019Dec 31, 2019-$13.31M–

More Foghorn Therapeutics figures

See a number that looks wrong?